| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | KR7290650001 ISIN |
| KR Country | 128 Employees | 29 Dec 2025 Last Dividend | 12 Oct 2020 Last Split | - IPO Date |
L&C Bio Co., Ltd is engaged in the pioneering field of tissue regeneration medicine, focusing on the research and development of innovative solutions aimed at promoting healing and improving quality of life. Established in 2011, the company has quickly positioned itself as a leader in its sector. Headquartered in Seongnam-si, South Korea, L&C Bio leverages cutting-edge technology and scientific research to develop products that span across various applications, including human tissue engineering, medical devices, and cosmetic products. Its dedication to advancing tissue regeneration medicine reflects its commitment to addressing some of the most challenging medical issues faced today.
At the core of L&C Bio’s product lineup are human tissue products designed for medical applications requiring tissue regeneration and repair. These products are developed with the aim of facilitating faster recovery and better outcomes for patients undergoing surgical procedures or those in need of tissue regeneration due to injury or disease.
L&C Bio also ventures into the creation of medical devices that support or enhance the process of tissue healing and regeneration. Drawing from its research in tissue engineering, the company designs devices that can be used in various medical settings, contributing to the advancement of regenerative medicine practices.
Beyond its medical applications, L&C Bio has expanded its expertise into the development of cosmetic products. These products leverage the company’s background in tissue regeneration to offer solutions aimed at enhancing skin health and appearance, catering to a broader market with a focus on aesthetics and personal care.